We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CELSION WARNING LETTER DETAILS IRB VIOLATIONS
CELSION WARNING LETTER DETAILS IRB VIOLATIONS
June 11, 2004
On June 8 the FDA released a warning letter to biotechnology firm Celsion on May 7 that details violations discovered during the Phase I and Phase II trials of its Prolieve Thermodilatation system.